Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC., GlaxoSmithKline (GSK), Novartis AG and Novo Nordisk A/S.
The global biosimilar therapeutic peptides market is expected to grow from $0.93 billion in 2021 to $1.21 billion in 2022 at a compound annual growth rate (CAGR) of 30.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $3.50 billion in 2026 at a CAGR of 30.3%.
The biosimilar therapeutic peptides market consists of sales of biosimilar therapeutic peptides by the companies that are engaged in developing and commercialization of biosimilar peptides drugs for therapeutic applications.Peptide drugs are used as replacement therapies which supplements peptide hormones when the endogenous levels tend to decrease.
Biosimilar therapeutic peptides find its application in the treatment of cardiovascular diseases, metabolic diseases, respiratory conditions, cancer, and respiratory diseases.
The main types of biosimilar therapeutic peptides are innovative and generic.Biosimilar medications are frequently mistaken for generic drugs.
Both are marketed as low-cost knockoffs of high-priced name-brand medications.The main distinction is that generics are duplicates of synthetic pharmaceuticals, whereas biosimilars are based on drugs that contain biological organisms as active components.
The different routes of administration include parenteral route, transdermal route, others and is used in cancer, cardiovascular, central nervous systems, metabolic disorders, infection, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders.
North America was the largest region in the biosimilar therapeutics market in 2021.Middle East is expected to be the fargest growing region in the forecast period.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The increasing aging population is projected to surge the patients with chronic diseases contributing to the biosimilar therapeutic peptides’ market growth.Elderly people are more prone to various chronic diseases, surging the old age population rapidly across the world and is predicted to continue over the forecast period.
According to the World Health Organization (WHO), the world’s population over the age of 60 years is expected to reach 2 billion by the end of 2050.Moreover, according to the World Population Prospects, the 2019 Revision, the number of people aged 80 years and above is likely to increase from 143 million in 2019 to 426 million in 2050.
Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancer. The expected increase in the aging population suffering from various chronic conditions will drive the biosimilar market.
The long and costly drug approval process is expected to limit the growth of the biosimilar therapeutic peptides market over the upcoming years.The development, approval, and launch of new drugs is an expensive and prolonged procedure that includes expensive research stages.
A new drug has to go through four phases of clinical trials and screening by the regulatory body including Food and Drug Administration (FDA) (USA), Medicines and Healthcare Products Regulatory Agency (MHRA) (UK), and Medicines and Healthcare Products Regulatory Agency (MHRA) (India). According to a report of Tufts Center for the Study of Drug Development published by the Journal of Health Economics in 2019, a cost to develop new drugs is $2.6 billion whereas the approval rate for drugs entering clinical trail is less than 12%. Therefore, long and costly drug approvals of new drug candidates are anticipated to hinder the growth of biosimilar therapeutic peptides market.
During the forecast period, biosimilar therapeutic peptides market is expected to witness a growth in research collaborations as well as research funding approvals.Key companies are focusing on collaborations with companies and organizations to enhance their research & developments, expand their product portfolio, and geographical reach.
For instance, in January 2020, a UK-based biotechnology company focusing on developing a class of therapeutics based on its proprietary bicyclic peptide technology announced a collaboration with Cancer Research UK to develop BT7401, a new bicycle immune-oncology candidate.Cancer Research UK will fund and sponsor the development of a new candidate.
In addition to this, Sapience Therapeutics, Inc., a US-based biotechnology company focused on research & development on peptide therapeutics announced a research collaboration with the University of Bath (UK) to develop and discover new therapeutic agents for oncology applications. Hence, research collaborations to develop new therapeutic peptides is a major trend in the market.
In October 2019, Zealand Pharma A/S, a Denmark-based biotechnology company specializing in the discovery and development of innovative peptide-based medicines acquired Encycle Therapeutics, Inc. for up to $80 million. The acquisition is expected to strengthen the Zealand Pharma A/S in the peptide therapeutics and in targeting gastrointestinal diseases with the addition of orally delivered preclinical macrocycle peptide. Encycle Therapeutics, Inc. is a Canada-based biotechnology company specializing in unique platform technology that allows the synthesis of macrocyclic peptides demonstrating improved drug-like properties.
The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Our reports have been used by over 10K customers, including:
The global cell separation technologies market reached a value of US$ 7.62 Billion in 2021. Looking forward, the analyst expects the market to reach a value of US$ 19.28 Billion by 2027, exhibiting a CAGR of 16.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well...
Achondroplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Achondroplasia - Drugs In Development, 2022, provides an overview of the Achondroplasia (Musculoskeletal Disorders)...
Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Neuronal acetylcholine receptor subunit beta-2 is a protein...
The global humectants market reached a value of US$ 24.6 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 37.9 Billion by 2027, exhibiting a CAGR of 7.6% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the...
120 pages •
By Infiniti Research Limited
• Jun 2022
Global Automated Liquid Handlers Market 2022-2026 The analyst has been monitoring the automated liquid handlers market and it is poised to grow by $ 242.84 million during 2022-2026, accelerating at a CAGR of 5.95% during the forecast period. Our report on the automated liquid handlers market provides a holistic analysis,...
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
The global albumin market reached a value of US$ 5.4 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 7.7 Billion by 2027, exhibiting a CAGR of 6.15% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic...
Female Hypoactive Sexual Desire Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder - Drugs In Development, 2022, provides an overview...
Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules...
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Neuropeptide Y Receptor Type 2 - Drugs In Development, 2022’; Neuropeptide...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.